Generate Biomedicines, Inc. filings document public-company events, financial results, governance changes, capital structure, and clinical portfolio disclosures. The company's Form 8-K reports include quarterly results and business updates covering its generative biology platform and named programs such as GB-0895, GB-4362, and GB-5267.
Filings also describe IPO-related governance documents, including the amended and restated certificate of incorporation and bylaws, authorized common and preferred stock, stockholder meeting procedures, advance-notice provisions, and board authority over undesignated preferred stock. Registration and event disclosures provide formal records of the company's transition to a Nasdaq-listed clinical-stage biotechnology issuer.
Generate Biomedicines, Inc. reports Schedule 13G disclosures from Flagship-related entities showing aggregated control positions in Common Stock. The filing lists shares outstanding of 128,192,484 as of March 31, 2026. The excerpt shows Flagship Pioneering, LLC holds 62,673,117 shares (48.9%) and related Flagship vehicles hold multiple additional positions, including Flagship VentureLabs VI, LLC: 25,016,458 shares (19.5%), Flagship Pioneering Fund VII, L.P.: 16,827,224 shares (13.1%), and Flagship Pioneering Fund VI, L.P.: 12,723,940 shares (9.9%). The filing identifies the Reporting Persons, their addresses, citizenships, and the voting/dispositive power reported for each entity.
Generate Biomedicines, Inc. executive Michael Nally reported beneficial ownership of 6,919,051 shares of Common Stock, representing 5.2% of the class as of March 31, 2026. The filing cites 128,192,484 shares outstanding as of March 31, 2026. The reported stake includes 4,029,897 shares underlying stock options exercisable within 60 days and several record holdings across trusts and a GRAT. The statement is a beneficial ownership disclosure under Schedule 13G and is signed by Michael Nally on May 15, 2026.
Generate Biomedicines, Inc. reports first-quarter 2026 results as a newly public, clinical-stage biotech focused on AI-driven protein therapeutics. Collaboration revenue was $7.2 million, while operating expenses of $71.3 million led to a net loss of $61.7 million. Research and development spending rose to $57.8 million as the company advanced GB-0895 into Phase 3 severe asthma trials and prepared first-in-human studies for GB-4362 and GB-5267. Net cash used in operating activities was $80.4 million. After its IPO, which generated $369.3 million in net proceeds, cash, cash equivalents and marketable securities reached $516.6 million as of March 31, 2026, and management expects this to fund operations into the first half of 2028.
Generate Biomedicines, Inc. reported first quarter 2026 results, combining a recent IPO cash infusion with higher investment in its pipeline. Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, reflecting $369.3 million in net IPO proceeds and supporting an expected cash runway into the first half of 2028.
Collaboration revenue for the quarter was $7.2 million, while research and development expenses rose to $57.8 million and general and administrative expenses to $13.5 million, driven partly by Phase 3 work on GB-0895 and public-company costs. Net loss attributable to common stockholders widened to $69.2 million, and net cash used in operating activities was $80.4 million for the quarter.
The company highlighted continued advancement of its generative biology platform and clinical programs, including Phase 3 trials of GB-0895 in severe asthma, ongoing development in COPD, and oncology programs GB-4362 and GB-5267, with GB-4362 holding FDA Fast Track designation.
Pioneering Medicines 02, LLC, a major holder of Generate Biomedicines, Inc., reported indirect ownership of 1,562,500 shares of Common Stock. The filing is an initial ownership report, not a new trade, and notes a control chain through various Flagship Pioneering entities with beneficial ownership disclaimed beyond any pecuniary interest.
Generate Biomedicines, Inc. Chief Executive Officer Michael Nally purchased 20,000 shares of common stock in an open-market transaction at $12.00 per share. Following this purchase, he directly owned 572,707 common shares, with additional indirect holdings reported through the MTN 2024 GST Trust and MTN 2024 GRAT.
Vessey Rupert reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines director Rupert Vessey was granted a new stock option award. The Form 4 reports an option over 29,561 shares of Generate Biomedicines, Inc. common stock, held directly. Following this grant, he holds 29,561 derivative securities.
The footnote states that all shares underlying this option will vest in full on February 19, 2027, provided he continues to serve through that vesting date. This is an equity compensation grant rather than an open-market share purchase or sale.
Generate Biomedicines, Inc. Chief People Officer Beth Grous reported two insider transactions. An account held by her spouse bought 300 shares of common stock at $16.00 per share, recorded as indirect ownership. She also received a grant of 114,020 stock options, which vest in forty-eight equal monthly installments starting after February 19, 2026, contingent on continued service.
Generate Biomedicines director Frances Arnold received a stock option grant for 29,561 shares. The option was awarded at an exercise price of $0.00 per share and increases her directly held derivative position to 29,561 options. These options are scheduled to vest in full on February 19, 2027, if she continues serving through that date.
Generate Biomedicines, Inc. Chief Medical Officer Laurie Anne Lee reported an award of stock options covering 42,230 shares on February 26, 2026. These options were granted at an exercise price of $0.00 per share and will vest in 48 equal monthly installments following February 19, 2026, as long as she continues in service.